Investor Ideas #Potcasts 544, #Cannabis News and #Stocks on the Move; (NASDAQ: $NEPT) (TSX: $NEPT.TO), (CSE: $CURA.C) (OTCQX: $CURLF), (OTC: $MJNA), (CSE: $OPTI.C) (CSE: $SILO.C)
Delta, Kelowna, BC, March 23, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/032321-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/03231NEPT-CURA-MJNA-OPTI-SILO.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, today announced that Health Canada has provided the Company with a license amendment to allow it to sell dried cannabis flower and pre-rolled cannabis in the Canadian recreational market.
Neptune currently supplies the market with premium cannabis extracts, under its Mood Ring™ and PanHash™ brands, and will expand its offering to include all regulated product categories. This empowers the Company to provide a comprehensive portfolio, enhance its total addressable market and target the lucrative flower segment, which is a dominant force in the industry both in sales and revenue.
"Dried flower and associated products derived therefrom will be the latest additions to Neptune's collection of cannabis products, which includes High CBD Oil, High CBD Oil Capsules and Legacy Hashish," said Neptune Wellness Solutions' President and Chief Executive Officer Michael Cammarata.
The license amendment enables Neptune to leverage trusted partnerships across its supply chain to acquire unique and highly sought-after cultivars. The Company's dried flower will be carefully selected and curated by an award-winning cannabis sommelier, and then hand packaged in premium packaging. This ensures that the integrity and quality of the carefully sourced flower will be maintained and preserved to provide supreme quality for the customer. The ability to source exceptional flower from any licensed producer will afford flexibility to maximize emerging commercial opportunities and will safeguard Neptune from increased industry volatility.
"This is a very exciting time for Neptune, allowing us to sell all categories of recreational cannabis to meet the demands of our Canadian consumers," said Mr. Cammarata. "We are excited to bring to market premium dried cannabis flower products that are packaged to preserve their quality and profile."
Today's announcement follows Neptune Wellness Solutions Inc. entering into a letter of intent with Société québécoise du cannabis (SQDC), the province's sole legal retailer for recreational cannabis, for the sale of Neptune's new cannabis brand, PanHash™.
As Neptune continues to redefine the recreational cannabis market, the Company has pledged to align with cultivators that share its core values of sustainability, accountability and excellence to furnish the industry with superior cannabis flower. All cannabis products are manufactured and packaged at the Company's purpose-built facility in Sherbrooke, Quebec.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading U.S. provider of consumer products in cannabis, today launched Select Squeeze, a fast-acting THC-infused beverage enhancer featuring Nano-emulsification technology. In addition to the product's innovative nature, the debut of Select Squeeze marks a significant milestone as one of the cannabis industry's widest national product launches. Select Squeeze is among the first cannabis products with mass availability as it becomes accessible to a total addressable population of 94 million adults age 21+.
Select, known as America's #1 Cannabis Oil Brand, has a variety of best-in-class cannabis products in over 1500 locations across 18 states. The curation of those products is unique to each market, reflecting the various regulations at a local level. Continuing on its path to becoming the first nationally recognized cannabis brand, Select is determined to provide patients and customers with consistent access to the products they know and trust. Starting this week, Select Squeeze is launching simultaneously across nine states including Arizona, Colorado, Connecticut, Massachusetts, Maine, Oklahoma, Oregon, Utah and Vermont. In April, Select Squeeze will launch in an additional five states including California, Florida, Illinois, Nevada and Ohio.
Select Squeeze is an advanced formulation that utilizes Nanotechnology to transform any beverage into a THC-infused, flavor-enhanced experience. By turning cannabis oil into tiny water-soluble molecules, the THC compounds not only dissolve evenly into any beverage but are also more rapidly and efficiently absorbed into the bloodstream, with effects felt in as little as 15-30 minutes, significantly faster than traditional edibles. The product's intuitive, proprietary bottle design features a unique fill-and-pour reservoir that makes precision dosing more straightforward than ever. The compact design also makes it ideal for discreet enjoyment on the go. Select Squeeze will launch with four flavor varieties, including Lemon-Lime, Watermelon, Strawberry Lemonade, and Hint of Sweet, allowing effective flavor pairings with a wide range of beverages, hot or cold.
"Curaleaf has been on the forefront of creating sophisticated cannabis experiences and introducing high-quality, consistent consumer products in a variety of form functions," said Joe Bayern, CEO of Curaleaf. "We're incredibly excited to launch Select Squeeze across multiple states, as this new product not only addresses the rising market demand for edibles and beverage products but also underscores the mainstream adoption of cannabis products across a diverse array of U.S. consumers."
With the launch of Select Squeeze today, Select products are currently available in 18 states, including Arizona, California, Colorado, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan, Maryland, New York, Nevada, Ohio, Oklahoma, Oregon, Pennsylvania, Utah, and Vermont. Squeeze will sit alongside a full lineup of Select vape products (Elite, Elite Live, Fresh and Essentials), as well as edibles and sublingual products, which include Select's Classic Gummies, Nano Gummies, and Ratio Drops. To find out more about Select's portfolio of products or find a dispensary near you that carries Select products, go to www.selectbetter.com.
Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, reports today that its subsidiary Kannaway® participated in, and today announces the recent positive results, of the Validcare clinical study. The study used Kannaway®’s hemp-derived cannabidiol (CBD) products as a part of its efforts to meet the Food and Drug Administration (FDA)’s request for data on the use of botanical CBD with regard to potential liver toxicity issues, which seem to occur with the pharmaceutical version of CBD.
According to Validcare’s team of principal investigators, the study showed no evidence of liver toxicity in the 839 trial participants who ingested oral forms of hemp-derived CBD for a minimum of 60 days. The investigators met with the Food and Drug Administration (FDA) Cannabis Product Council (formerly known as the Cannabis Work Group) on Monday, March 15, to share these findings and answer the organization’s March 5, 2020, request for science-based data to help determine the appropriate regulatory path for hemp-derived CBD products. Blood markers for ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), ALP (Alkaline Phosphatase), and Bilirubin levels were examined during the study.
“These study results help support the work that we’ve been doing in Mexico and Brazil to study CBD’s safety and efficacy,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We hope to continue to participate in similar future studies so that the world can continue to have expanded access to high-quality botanical products. I am glad to see participating stakeholders with longer-term visions banding together to make industry-wide progress that ultimately will benefit end consumers. Our company is involved with similar research in Europe in conjunction with the European Industrial Hemp Association (EIHA).”
Brands that participated in this study provided funding, product, certificates of authenticity, and assisted with the recruitment of adult US-based consumers. The use of Validcare’s decentralized clinical research platform and partnership with national laboratories enabled participants and principal investigators to successfully complete this first cohort, despite the pandemic, and compile and deliver results to brands and the FDA within six weeks.
“As the creators of some of the first testing measures for the entire CBD industry, many that are still used by other companies today, we are proud to be a part of this study and continue to be leaders in CBD safety testing,” said Kannaway® CEO Blake Schroeder. “Providing the highest-quality, safest products on the market is something we are proud of.”
Optimi Health Corp. (CSE: OPTI), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, provided the following overview and update of its facility construction and Controlled Substance Dealer Licensing activities to-date.
Optimi began construction of its two adjacent 10,000 square foot facilities in Princeton, British Columbia in August of 2020. Phase One included all civil engineering including perimeter controls, foundations, building exteriors, water and sewerage connections, interior drainage, and flooring, which have been completed and approved. (See Figure 1)
The second phase which commenced in January 2021, involves a comprehensive pharmaceutical grade interior buildout of the functional mushroom cultivation and processing facility including state-of-the-art machinery and processing equipment as well as an advanced analytics laboratory, and is expected to reach completion this summer with final preparations to commence planting in Q3, 2021 with a subsequently anticipated 50-day timeline to inaugural harvest. The environmental design employs highly efficient clean room technology throughout the facility. The Optimi team brings previous successful experience with similar technology which is being leveraged to make an application for valuable power consumption energy grants offering significant cost advantages on an annualized basis.
As a result of unusually mild winter conditions, and rapid adoption of pandemic health and safety measures, the Optimi team is pleased to report that Phase One completed ahead of schedule and below the projected cost estimate, with the entire project currently within the originally proposed $8.2 million budget.
It is anticipated that April will bring a stage-3 security inspection under the auspices of the Office of Controlled Substances (OCS) which manages applications for Controlled Drugs and Substances Dealer's Licences submitted in accordance with the Controlled Drugs and Substances Act (CDSA). The Company has completed the application intake and review phase and is confident the facility meets or exceeds the legally required security obligations. The inspection should lead to a timely decision to grant a Dealer’s License thereby enabling the Company to commence production and research into psilocybin-derived psychedelic compounds, concurrent with its functional mushroom commercial retail operations.
Optimi Health COO and Director, Bryan Safarik, comments, “Our efforts in Princeton are moving ahead rapidly and every day brings us ever closer to our goals. We’re ahead of schedule, under budget, and perhaps most importantly, the civic leadership have been extraordinarily supportive. I want to personally thank Mayor Spencer Coyne and economic development director Gray Schatz for their ongoing commitment and support. Interest in what we are doing has seen us receive many excellent resumes with strong science backgrounds. We have been approached by numerous professors and researchers across North America reaching out to work with Optimi as interest in the mushroom sector continues to grow. The year ahead is looking even more promising than I had envisioned when we began, and the entire team is excited by the promise of so many positive and rewarding opportunities ahead.”
Silo Wellness Inc. (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces and Ehave, Inc. (OTC: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to collaborate on a data- study in coordination with select volunteer participants of Silo Wellness’ Jamaican psilocybin-facilitated wellness retreats.
The study will focus on studying transitions in and out of the altered state of consciousness caused by psychedelic molecules and offer a safe and powerful means of advancing knowledge on the neurobiology of non-ordinary conscious states. Advancing the understanding of the neurobiological underpinnings of immersive states of consciousness could ultimately help researchers find better treatment approaches for diseases such as chronic pain, depression (major and persistent), bipolar disorder, general anxiety, ADHD and Schizophrenia. Ehave’s proprietary dashboard will be used to collect and sort data from the brain mapping study.
Ehave will integrate Brain Scientific's NeuroCap and NeuroEEG to acquire data from participants in real time. The study with Silo Wellness will allow Ehave to deploy NeuroCap and NeuroEEG in order to capture the data around the electrophysiological changes in brain pre-, mid-, and post-psychedelic drug administration. This will allow researchers to measure the efficacy of psychedelic molecules on various mental health indications that might open new doorways for psychedelic research and development of molecules to address various mental health disorders with great precision and efficiency.
Ehave CEO, Ben Kaplan said, “Brain mapping reveals which areas of the brain are not working the way they should, as well as how those areas are affected by external factors." Mr. Kaplan continued, "The brain mapping process will allow us to see inside the brain to identify the effects of psilocybin molecules and its derivatives on brainwaves. From the data we receive from the brain map, a report will be generated for each patient that shows the areas affected.”
“Silo Wellness is delighted to collaborate on discovering innovative methods to assist in delivering the most optimal experience of wellness retreat participants through the screening of psychoactivity, which may enable us to learn even more about therapeutic dosing of psilocybin products,” commented Douglas K. Gordon, Chief Executive Officer of Silo Wellness. “Scientific approaches such as this align with our ongoing commitment to leverage technology, applications and formats, such as our patent-pending psilocybin nasal spray, to both destigmatize and transform the psychedelics landscape.”
The study will assimilate data of select volunteers of Jamaican psilocybin retreat participants by measuring brain activity for a duration of 15-30 minutes before the administration of psilocybin and its derivatives. The participant shall wear an EEG neurocap during the entire process of the study and for 15-30 minutes after the administration of the psilocybin and its derivatives.
"This study will be conducted using EEG devices to measure the brain activity before, during, and after administration of psilocybin and its derivatives. To conduct the test, we place a comfortable cap on the individual’s head. The cap contains sensors that measure brainwaves of various frequencies. This is an entirely non-invasive reading of the brain’s activity and frequency patterns," said Alfred Farrington II, Chief Information Officer of Ehave.
Dr. Manideep Gopishetty, Medical Advisor for Ehave said, “Understanding the effects psychedelics have on human brain activity and how it’s impacting the consciousness could be a key to building a more sustainable and effective treatment protocol for various mental health disorders.”
“This is part of Silo Wellness’s commitment to the advancing psychedelic compounds in familiar delivery modalities,” stated pharmacologist Dr. Parag Bhatt, Silo medical advisor and co-inventor of the nasal spray. “We are using this endeavor to evaluate the feasibility of an advanced tool to potentially use in a future study to prevent hyper-therapeutic dosing of psychedelics in line with our psilocybin nasal spray and other metered-dosing patent application claims.”
Ehave will be responsible for collecting and sorting data from the brain mapping study with its Ehave Dashboard. Ehave will also be responsible for designing the protocol for the brain mapping study, finalizing the principal investigator and medical monitor, providing the EEG equipment, as well as training the ground staff in Jamaica to handle the EEG equipment.
In addition to developing and facilitating the psilocybin-assisted wellness retreat agenda, Silo Wellness will be responsible for procuring the retreat sites for the brain mapping study to take place in Jamaica. Silo Wellness will also be responsible for facilitating the administration of psilocybin and its derivatives in natural variants.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Or www.potcasts.ca
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Play Music and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more
Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
